PECAM1 and neoplasm: Targeted immunohistochemistry showed tumor cell positivity for cytokeratin, nuclear beta-catenin, CD56, dot-like CD99, progesterone receptor (focal), and aberrant focal CD31 expression, with negativity for ERG and other vascular markers, confirming the diagnosis of SPN.